Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 980.25% | 419.56% | 4,608.33% | 2,407.14% | 315.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 980.25% | 419.56% | 4,608.33% | 2,407.14% | 315.38% |
| Cost of Revenue | 47.17% | 22.41% | 19.77% | 6.12% | 66.38% |
| Gross Profit | -38.49% | -13.56% | -10.59% | -1.30% | -65.46% |
| SG&A Expenses | 22.85% | 30.61% | 67.50% | 99.69% | 156.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.43% | 27.93% | 49.08% | 56.53% | 115.24% |
| Operating Income | -28.33% | -25.12% | -45.57% | -54.36% | -114.90% |
| Income Before Tax | -28.28% | -18.98% | -51.55% | -63.17% | -116.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.28% | -18.98% | -51.55% | -63.17% | -116.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.28% | -18.98% | -51.55% | -63.17% | -116.04% |
| EBIT | -28.33% | -25.12% | -45.57% | -54.36% | -114.90% |
| EBITDA | -28.47% | -25.22% | -45.63% | -54.40% | -115.25% |
| EPS Basic | 13.09% | 21.61% | -16.69% | -25.68% | -54.30% |
| Normalized Basic EPS | 13.03% | 21.61% | -16.76% | -25.74% | -54.19% |
| EPS Diluted | 13.09% | 21.61% | -16.69% | -25.68% | -54.30% |
| Normalized Diluted EPS | 13.03% | 21.61% | -16.76% | -25.74% | -54.19% |
| Average Basic Shares Outstanding | 47.59% | 51.79% | 29.83% | 29.78% | 40.03% |
| Average Diluted Shares Outstanding | 47.59% | 51.79% | 29.83% | 29.78% | 40.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
